Effects of Long-term Use of Antiretroviral Therapy on the Prevalence of Oral Epstein-Barr Virus

Overview

Journal J Oral Pathol Med

Specialties Dentistry
Pathology

Date 2011 Oct 11

PMID 21981060

Citations 3

Authors

Korntip Amornthatree

Hutcha Sriplung

Winyou Mitarnun

Wipawee Nittayananta

Affiliations

Soon will be listed here.

Abstract

Background: The objectives of this study were to determine (i) the prevalence of oral Epstein-Barr virus (EBV) in HIV-infected subjects compared to non-HIV controls and (ii) the effects of long-term use of antiretroviral therapy (ART) on the prevalence of oral EBV.

Methods: A cross-sectional study was performed in HIV-infected subjects with and without ART, and non-HIV individuals. DNA in saliva samples was extracted and used as a template to detect EBV BamH1W and EBNA1 by quantitative polymerase chain reaction. Student t-test and ANOVA test were performed to determine the prevalence rates among groups.

Results: Forty-nine HIV-infected subjects: 37 on ART (age range 23-54 year, mean 37 year), 12 not on ART (age range 20-40 year, mean 31 year), and 20 non-HIV controls (age range 19-53 year, mean 31 year) were enrolled. The numbers of EBV BamH1W in saliva were found to be significantly higher in HIV-infected subjects than non-HIV controls (80% vs. 20%, mean = 12118 vs. 134 copies/10(5) cells, P < 0.001). HIV-infected subjects who were on ART had significantly lower numbers of EBV BamH1W than those who were not (mean = 4102 vs. 138613 copies/10(5) cells, P = 0.011). The numbers were significantly lower in those who received long-term ART compared with short-term (mean = 1401 vs. 11124 copies/10(5) cells, P = 0.034). No significant difference was observed between the groups when using EBNA1 primers.

Conclusions: Prevalence of oral EBV was significantly higher in HIV-infected subjects than non-HIV-controls. The numbers of the virus were significantly decreased by ART. Long-term use of ART did not increase oral EBV.

Citing Articles

Oral Cytokine Levels Are More Linked to Levels of Plasma and Oral HIV-1 RNA Than to CD4 T-Cell Counts in People With HIV.

Rocco J, York Z, Shen C, Shiboski C, Cyriaque-Webster J, McLaughlin J Open Forum Infect Dis. 2020; 7(3):ofaa047.

PMID: 32158775 PMC: 7051037. DOI: 10.1093/ofid/ofaa047.

Evaluation of Epstein-Barr Virus Salivary Shedding in HIV/AIDS Patients and HAART Use: A Retrospective Cohort Study.

Yan Y, Ren Y, Chen R, Hu J, Ji Y, Yang J Virol Sin. 2018; 33(3):227-233.

PMID: 29654554 PMC: 6178557. DOI: 10.1007/s12250-018-0028-z.

Prevalence of salivary Epstein-Barr virus in potentially malignant oral disorders and oral squamous cell carcinoma.

Bagan L, Ocete-Monchon M, Leopoldo-Rodado M, Murillo-Cortes J, Diaz-Fernandez J, Medina-Gonzalez R Med Oral Patol Oral Cir Bucal. 2016; 21(2):e157-60.

PMID: 26827058 PMC: 4788793. DOI: 10.4317/medoral.20785.

References

Hung C, Hsiao C, Wang J, Chen M, Hsieh S, Sheng W . Herpes zoster in HIV-1-infected patients in the era of highly active antiretroviral therapy: a prospective observational study. Int J STD AIDS. 2005; 16(10):673-6. DOI: 10.1258/095646205774357271. View

Purdue M, Lan Q, Martinez-Maza O, Oken M, Hocking W, Huang W . A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. Blood. 2009; 114(13):2730-2. PMC: 2756127. DOI: 10.1182/blood-2009-04-217521. View

. Classification and diagnostic criteria for oral lesions in HIV infection. EC-Clearinghouse on Oral Problems Related to HIV Infection and WHO Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus. J Oral Pathol Med. 1993; 22(7):289-91. View

Jansen C, Piriou E, De Cuyper I, van Dort K, Lange J, Miedema F . Long-term highly active antiretroviral therapy in chronic HIV-1 infection: evidence for reconstitution of antiviral immunity. Antivir Ther. 2006; 11(1):105-16. View

Engels E . Non-AIDS-defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities. AIDS. 2009; 23(8):875-85. PMC: 2677638. DOI: 10.1097/QAD.0b013e328329216a. View

Murillas J, Del Rio M, Riera M, Vaquer P, Salas A, Leyes M . Increased incidence of hepatocellular carcinoma (HCC) in HIV-1 infected patients. Eur J Intern Med. 2005; 16(2):113-115. DOI: 10.1016/j.ejim.2004.09.011. View

Ho D . Time to hit HIV, early and hard. N Engl J Med. 1995; 333(7):450-1. DOI: 10.1056/NEJM199508173330710. View

Ramos da Silva S, Elgui De Oliveira D . HIV, EBV and KSHV: viral cooperation in the pathogenesis of human malignancies. Cancer Lett. 2011; 305(2):175-85. DOI: 10.1016/j.canlet.2011.02.007. View

Hessol N, Seaberg E, Preston-Martin S, Massad L, Sacks H, Silver S . Cancer risk among participants in the women's interagency HIV study. J Acquir Immune Defic Syndr. 2004; 36(4):978-85. DOI: 10.1097/00126334-200408010-00013. View

10.

Deyrup A . Epstein-Barr virus-associated epithelial and mesenchymal neoplasms. Hum Pathol. 2008; 39(4):473-83. DOI: 10.1016/j.humpath.2007.10.030. View

11.

Miller C, Berger J, Mootoor Y, Avdiushko S, Zhu H, Kryscio R . High prevalence of multiple human herpesviruses in saliva from human immunodeficiency virus-infected persons in the era of highly active antiretroviral therapy. J Clin Microbiol. 2006; 44(7):2409-15. PMC: 1489493. DOI: 10.1128/JCM.00256-06. View

12.

Cinque P, Cingolani A, Bossolasco S, Antinori A . Positive predictive value of Epstein-Barr virus DNA detection in HIV-related primary central nervous system lymphoma. Clin Infect Dis. 2004; 39(9):1396-7. DOI: 10.1086/425132. View

13.

Stevens S, Blank B, Smits P, Meenhorst P, Middeldorp J . High Epstein-Barr virus (EBV) DNA loads in HIV-infected patients: correlation with antiretroviral therapy and quantitative EBV serology. AIDS. 2002; 16(7):993-1001. DOI: 10.1097/00002030-200205030-00005. View

14.

Mwakigonja A, Kaaya E, Heiden T, Wannhoff G, Castro J, Pak F . Tanzanian malignant lymphomas: WHO classification, presentation, ploidy, proliferation and HIV/EBV association. BMC Cancer. 2010; 10:344. PMC: 2909982. DOI: 10.1186/1471-2407-10-344. View

15.

Piriou E, Jansen C, van Dort K, De Cuyper I, Nanlohy N, Lange J . Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy. J Immunol. 2005; 175(3):2010-7. DOI: 10.4049/jimmunol.175.3.2010. View

16.

Ling P, Vilchez R, Keitel W, Poston D, Peng R, White Z . Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2003; 37(9):1244-9. DOI: 10.1086/378808. View

17.

Kis A, Feher E, Gall T, Tar I, Boda R, Toth E . Epstein-Barr virus prevalence in oral squamous cell cancer and in potentially malignant oral disorders in an eastern Hungarian population. Eur J Oral Sci. 2009; 117(5):536-40. DOI: 10.1111/j.1600-0722.2009.00660.x. View

18.

Thomison 3rd J, Thomas L, Shroyer K . Human papillomavirus: molecular and cytologic/histologic aspects related to cervical intraepithelial neoplasia and carcinoma. Hum Pathol. 2008; 39(2):154-66. DOI: 10.1016/j.humpath.2007.11.002. View

19.

Gillison M . Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection. Curr Opin Oncol. 2009; 21(5):439-44. DOI: 10.1097/CCO.0b013e32832f3e1b. View

20.

Nikoobakht M, Beitollahi J, Nikoobakht N, Aloosh M, Sahebjamee M, Rezaeidanesh M . Evaluation of Epstein-Barr virus load in saliva before and after renal transplantation. Transplant Proc. 2011; 43(2):540-2. DOI: 10.1016/j.transproceed.2011.01.004. View